telehealth.helpFind my match

Home WikiTelehealth Concepts

STEP trials

From WikiTelehealth, the telehealth.help reference · Last updated

The STEP trials (Semaglutide Treatment Effect in People with obesity) are the phase 3 clinical trials of once-weekly semaglutide 2.4 mg for weight management run by Novo Nordisk. Their results supported the 2021 FDA approval of Wegovy.

STEP trials
Drug studiedSemaglutide 2.4 mg weekly injection
SponsorNovo Nordisk
Phase3
Typical length68 weeks
Led toWegovy approval (June 4, 2021)
Related trialSELECT (heart outcomes)

Overview

The STEP program tested weekly semaglutide 2.4 mg against placebo, or against other treatment, in adults with obesity or overweight. Each trial added a lifestyle program of diet and exercise. Most ran for 68 weeks.

The trials looked at different groups and questions: people without diabetes, people with type 2 diabetes, people in an intensive behavior program, what happens when the drug is stopped, and longer use.

Main trials

STEP 1 was the main trial in adults without diabetes. People on semaglutide lost 14.9% of their body weight on average after 68 weeks, compared with 2.4% on placebo. About 47.9% of people on semaglutide lost at least 15% of their weight.

In STEP 2, adults with overweight or obesity and type 2 diabetes lost 9.6% of their body weight on average with semaglutide 2.4 mg after 68 weeks, vs. 3.4% on placebo. Weight loss is usually smaller in people with diabetes.

STEP 3 combined semaglutide with intensive behavioral therapy and a low-calorie diet at the start. STEP 5 followed people for 2 years. STEP 8 compared weekly semaglutide with daily liraglutide 3.0 mg in adults without diabetes.

Stopping treatment

Two STEP studies looked at what happens after semaglutide stops. In STEP 4, people who kept taking semaglutide after a 20-week run-in lost another 7.9% of their body weight by week 68, while people switched to placebo regained 6.9%.

In the semaglutide trial extension, people regained about two-thirds of the weight they had lost within a year of stopping. Researchers concluded that obesity behaves like a chronic condition and that weight tends to return when treatment ends.

The FDA approved semaglutide 2.4 mg as Wegovy on June 4, 2021, based mainly on STEP 1 to 4. A separate outcome trial, SELECT, tested whether semaglutide lowers heart risk. In SELECT, a heart attack, stroke or cardiovascular death occurred in 6.5% of people on semaglutide and 8.0% of people on placebo over a mean follow-up of about 40 months (hazard ratio 0.80). That result led to the 2024 heart indication for Wegovy.

Results for the main tirzepatide program are in the article on the SURMOUNT trials. Our medication comparison puts the trial results side by side.

Compare GLP-1 medications

See also

References

  1. Wilding et al., NEJM 2021;384:989-1002 (STEP 1). pubmed.ncbi.nlm.nih.gov
  2. Davies et al., Lancet 2021;397:971-984 (STEP 2). pubmed.ncbi.nlm.nih.gov
  3. Wadden et al., JAMA 2021;325:1403-1413 (STEP 3). pubmed.ncbi.nlm.nih.gov
  4. Rubino et al., JAMA 2021;325:1414-1425 (STEP 4). pubmed.ncbi.nlm.nih.gov
  5. Wilding et al., Diabetes Obes Metab 2022;24:1553-1564 (STEP 1 extension). doi.org
  6. Lincoff et al., NEJM 2023;389:2221-2232 (SELECT). pubmed.ncbi.nlm.nih.gov

Last updated . Category: Concepts. Browse all 38 WikiTelehealth entries.